Navigation Links
InfuSystem Appoints Bryan Russo as Chief Commercial Officer
Date:4/27/2009

MADISON HEIGHTS, Mich., April 27 /PRNewswire-FirstCall/ -- InfuSystem (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced that it has hired Bryan Russo as Chief Commercial Officer of the company. In this newly formed position, Mr. Russo will be responsible for overseeing sales and expanding the company's market presence.

Prior to joining InfuSystem, Mr. Russo was Regional Vice President of Sales at Gentiva Health Services, Inc., the nation's largest home healthcare company with a specialty in skilled nursing, physical therapy, occupational therapy and speech pathology within the Medicare population. Over his tenure there, he led the sales and marketing effort and was instrumental in the company achieving overall net revenue growth of 35% and same store sales growth of over 25%. Prior to Gentiva, Mr. Russo was Regional Vice President of Sales at Concentra, Inc., one of the largest providers of health care services in the nation, serving patients at 234 medical centers in 40 states. In his role at Concentra, Mr. Russo was responsible for both national and regional sales and marketing. During his tenure at the company, revenue increased from $250 million to over $1.2 billion. Mr. Russo holds a BS/BA degree in Business from Villanova University.

Mr. Steve Watkins, Chief Executive Officer, commented, "Bryan's proven ability to build relationships, implement effective marketing initiatives and drive sales in the home healthcare arena make him a valuable addition to our team. We welcome Bryan on board and look forward to his contributions to gain deeper and broader penetration of our ambulatory infusion pumps and associated clinical services within the oncology market."

About InfuSystem Holdings, Inc.

InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.


'/>"/>
SOURCE InfuSystem Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InfuSystem Pays Down Term Loan by $6.1 Million Year-to-Date
2. InfuSystem Holdings Reports 12.9% Revenue Increase and $3.3 Million of Adjusted EBITDA for the Fourth Quarter of 2008
3. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
4. InfuSystem Holdings Appoints Two New Board Members
5. Slimband Expands Surgical Team and Appoints New Surgeon Dr. Jamie Cyriac (MD, FRCS (C), FACS)
6. Tigris Pharmaceuticals Appoints Pedro Granadillo as Chairman of Board of Directors
7. NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice
8. DecisionView Board of Directors Appoints James P. Scullion as CEO and President
9. Air Products Appoints John Marsland VP and GM of Global Liquid Bulk, Generated Gases, and Helium
10. VELOCITY Broadcasting Appoints Two Vice Presidents of Business Development
11. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: